EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›VERU

VERU

VERU INC.

Next earnings Aug 10, 2026 · consensus $-0.33 EPS

Last earnings -0.4% on 2026-05-13

Sell
$3.01
▲ 0.00%
$3.01▼ -51.45%
over 1Y
L $2.09EODHDH $6.95
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W+1.7%
1M+29.2%
3M+44.0%
YTD+32.6%
1Y-51.5%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Sell
Quality
C
Valuation
Fair value
Filings
Watch
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy

Conservative balance sheet (liabilities/equity 0.63x); but unprofitable (net margin -134.6%).

Revenue (FY2024) $16.9M · FY2024

VERU INC. shows $16.9M in FY2024 revenue (+3.6% YoY), a -134.6% net margin, and -124.0% ROE.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$61.3M$39.4M$16.3M$16.9M—
Gross profit$47.9M$30.6M$7.57M$5.85M—
Operating income$13.0M-$83.2M-$93.8M-$36.2M-$24.8M
Net income$7.39M-$83.8M-$93.2M-$37.8M-$22.7M
Diluted EPS$0.09-$1.05-$1.10——
Net margin12.1%-212.9%-571.6%-223.9%—

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$34.3M
EV / EBITDA—
EV / Sales2.0
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-47.0%
FCF yield-62.2%

Quality & risk

ROIC (est.)-97.3%
Free cash flow-$30.0M
Total debt$1.75M
Net cash$14.0M
Altman Z-Score-14.09 distress
Piotroski F-Score2/8

Capital returns

Buyback yield0.0%
Dividend yield (est.)0.0%
Shareholder yield0.0%
Shares Δ YoY-89.0%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Some governance/structural items recently, but no outright red flags.
  1. 8-K Other event2026-06-04
  2. 8-K Earnings results2026-05-13
  3. 10-Q Quarterly report2026-05-13
  4. S-3 Shelf registration (potential raise)2026-04-07
  5. S-3 Shelf registration (potential raise)2026-04-07
  6. 8-K Officer / director change2026-03-13
  7. 8-K Earnings results2026-02-11
  8. 10-Q Quarterly report2026-02-11
  9. DEF 14A Proxy statement2026-01-28

Recent filings

all on EDGAR ↗
8-KPeriod ending 2026-06-022026-06-04open ↗S-8Filing2026-05-13open ↗10-QPeriod ending 2026-03-312026-05-13open ↗8-KPeriod ending 2026-05-132026-05-13open ↗4Period ending 2026-05-042026-05-06open ↗4Period ending 2026-05-042026-05-06open ↗4Period ending 2026-05-042026-05-06open ↗4Period ending 2026-05-042026-05-06open ↗4Period ending 2026-05-042026-05-06open ↗4Period ending 2026-05-042026-05-06open ↗4Period ending 2026-05-042026-05-06open ↗4Period ending 2026-05-042026-05-06open ↗

Quality score

C
ValueGrowthProfitHealthMom.
ValueB
GrowthB+
ProfitabilityF
Financial healthC+
Momentum—
  • ✓Revenue growing year-over-year
  • ✗Profitable (positive net income)
  • ✗Net margin above 10%
  • ✗Return on equity above 15%
  • ✓Liabilities below 2× equity
Revenue
$16.9M
+3.6% YoY
Net margin
-134.6%
ROE
-124.0%
P/E
—

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$16.9M+3.6%
Net income-$22.7M+39.9%
Gross profit$5.85M-22.6%
Operating income-$24.8M+31.6%
Diluted EPS-$1.10-4.8%
Cash & equivalents$15.8M-36.6%
Total assets$29.8M-50.6%
Total liabilities$11.5M-59.1%
Stockholders' equity$18.3M-43.3%
Gross: 34.7%Op.: -146.6%L/E: 0.63x

Frequently asked

Is VERU INC. (VERU) a buy?
VERU currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.63x); but unprofitable (net margin -134.6%).
What is VERU INC.'s quality score?
VERU scores 55.58823529411764/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0000863894, latest 10-Q filed 2026-05-13) · EODHD · as of 6/26/2026, 7:21:17 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Dividends

Irregular
Yield (TTM)
—
Annual / share
—
Last ex-date
2014-04-28
Last amount
$0.70
ex 2014-04-28paid 2014-05-07$0.70
ex 2014-01-27paid 2014-02-05$0.70
ex 2013-10-28paid 2013-11-06$0.70
ex 2013-07-29paid 2013-08-07$0.70
ex 2013-04-29paid 2013-05-08$0.70
ex 2013-01-28paid 2013-02-06$0.60

Source: EODHD. Yield = trailing-12-month dividends ÷ price.

Earnings history

beat/miss · move
2026-05-13Beat +58.7% est▼ -0.44%8-K ↗
2026-02-11Beat +45.8% est▼ -0.43%8-K ↗
2025-12-17Beat +123.1% est▼ -8.61%8-K ↗
2025-08-12Beat +8.1% est▼ -11.70%8-K ↗
2025-05-08—▲ +4.15%8-K ↗
2025-02-13—▼ -4.45%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
Novo Nordisk Tests Wegovy Combinations In Older Adults With Veru TrialBullish
finance.yahoo.com· 2026-06-05
Top Biotech Gainers: VERU Teams Up With NVO, ABSI On Watch, ALVO Resubmits BLAs To FDA...Bullish
nasdaq.com· 2026-06-05
Earnings Scheduled For May 13, 2026Bullish
finance.yahoo.com· 2026-05-13
Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial ProgressBullish
globenewswire.com· 2026-05-13
Earnings week ahead: BABA, CSCO, PLUG, AMAT, JD, and moreBullish
seekingalpha.com· 2026-05-10
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight LossBullish
globenewswire.com· 2026-03-09

Vs tracked universe

compare →

1044 tracked peers · median

EDGAR Score56 vs 67
Revenue growth3.6% vs 7.1%
Net margin-134.6% vs 10.5%
Return on equity-124.0% vs 12.3%
P/E— vs 25.5

News sentiment

EODHD · 3d
Bullish
+0.18
vs typical · 5 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.